- Conditions
- Pulmonary Hypertension, Pulmonary Fibrosis, Sarcoidosis, Pulmonary
- Interventions
- iNO
- Combination Product
- Lead sponsor
- Bellerophon
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 6
- States / cities
- Miami, Florida • Cincinnati, Ohio • Philadelphia, Pennsylvania + 3 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 72
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Obesity, Interstitial Lung Disease, Chronic Obstructive Pulmonary Disease, Sarcoidosis, Pulmonary, Pulmonary Hypertension
- Interventions
- Semaglutide Pen Injector
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Sarcoidosis, Sarcoidosis, Pulmonary
- Interventions
- Observational Study
- Other
- Lead sponsor
- National Jewish Health
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2026
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Sarcoidosis, Pulmonary
- Interventions
- Namilumab, Placebo
- Drug
- Lead sponsor
- Kinevant Sciences GmbH
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 107 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 24
- States / cities
- Birmingham, Alabama • Palo Alto, California • Valencia, California + 21 more
- Conditions
- Sarcoidosis
- Interventions
- Not listed
- Lead sponsor
- Ohio State University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2012
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Interstitial Lung Disease, Sarcoidosis, Idiopathic Pulmonary Fibrosis, Pulmonary Fibrosis, Hypersensitivity Pneumonitis
- Interventions
- Not listed
- Lead sponsor
- University of Kansas Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2032
- U.S. locations
- 1
- States / cities
- Kansas City, Kansas
- Conditions
- Mesothelioma
- Interventions
- Multicycle SS1P, Pemetrexed, Cisplatin, Single cycle SS1P
- Biological · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2016
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Sarcoidosis, Pulmonary
- Interventions
- Acthar Gel, Placebo
- Drug
- Lead sponsor
- Mallinckrodt
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 29
- States / cities
- Birmingham, Alabama • Los Angeles, California • Denver, Colorado + 26 more
- Conditions
- Sarcoidosis
- Interventions
- all subjects will receive maraviroc 300mg orally twice a day for 6 weeks, Bronchoscopy with bronchoalveolar lavage, venipunctures, Skin biopsy
- Drug · Procedure
- Lead sponsor
- Kevin F. Gibson
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Pulmonary Sarcoidosis
- Interventions
- Mycophenolate
- Drug
- Lead sponsor
- Medical University of South Carolina
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2006
- U.S. locations
- 1
- States / cities
- Charleston, South Carolina
- Conditions
- Sarcoidosis, SARS-CoV2 Infection, Vaccine Response Impaired
- Interventions
- Assay of (1) the level of anti-spike IgG antibody, and (2) interferon-gamma release in response to SARS-CoV-2 antigen stimulation
- Diagnostic Test
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 101 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Sarcoidosis
- Interventions
- Placebo, Golimumab, Ustekinumab
- Drug
- Lead sponsor
- Centocor, Inc.
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 173 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 24
- States / cities
- Birmingham, Alabama • Los Angeles, California • Denver, Colorado + 21 more
- Conditions
- Sarcoidosis, Pulmonary Sarcoidosis
- Interventions
- Acthar gel
- Drug
- Lead sponsor
- University of Cincinnati
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Sarcoidosis, Precapillary Pulmonary Hypertension, Interstitial Lung Disease
- Interventions
- Inhaled Treprostinil
- Drug
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Idiopathic Pulmonary Fibrosis (IPF), Sarcoidosis Lung, Pulmonary Hypertension, Usual Interstitial Pneumonia
- Interventions
- Not listed
- Lead sponsor
- Cosmos Rx, Inc
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Norfolk, Virginia
- Conditions
- Sarcoidosis
- Interventions
- Riociguat, Placebo
- Drug
- Lead sponsor
- University of Cincinnati
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Interstitial Lung Diseases
- Interventions
- Not listed
- Lead sponsor
- Pulmonary Care and Research Collaborative Limited
- Other
- Eligibility
- Not listed
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Pulmonary Sarcoidosis
- Interventions
- PD 0360324, Normal Saline for injection
- Biological · Other
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 21 Years to 75 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013
- U.S. locations
- 5
- States / cities
- New York, New York • Cincinnati, Ohio
- Conditions
- Sarcoidosis, Pulmonary
- Interventions
- Not listed
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 200 participants
- Timeline
- 2023 – 2030
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • Dallas, Texas
- Conditions
- Sarcoidosis
- Interventions
- Blood draw, Bronchoscopy, Questionnaires
- Other · Procedure · Behavioral
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 30 Years to 60 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Emphysema, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis, Pulmonary Fibrosis, Bronchiectasis, Sarcoidosis, Pulmonary Hypertension, Alpha-1 Antitrypsin Deficiency
- Interventions
- Transplantation of lungs obtained from Non-Heart-Beating Donors (NHBDs) after ex-vivo perfusion w/ STEEN Solution™, STEEN Solution™
- Procedure · Device
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 15 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 2
- States / cities
- Chapel Hill, North Carolina • Durham, North Carolina
- Conditions
- Progressive Pulmonary Fibrosis
- Interventions
- BMS-986278, BMS-986278 Placebo
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 1,057 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 81
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 70 more
- Conditions
- Sarcoidosis, Pulmonary
- Interventions
- Pirfenidone, Placebos
- Drug
- Lead sponsor
- University of Cincinnati
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Cervical Cancer, Fallopian Tube Cancer, Head and Neck Cancer, Lung Cancer, Malignant Mesothelioma, Ovarian Cancer, Pancreatic Cancer, Primary Peritoneal Cavity Cancer
- Interventions
- SS1(dsFv)-PE38 immunotoxin
- Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2003
- U.S. locations
- 2
- States / cities
- Bethesda, Maryland • Winston-Salem, North Carolina